Accessibility Menu
Charles River Laboratories International logo

Charles River Laboratories International(NYSE) CRL

Market Cap$11.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+964%
5 Year-43%
1 Year+39%
1 Month+1%
$259.39
+10.79%
+25.27Today
Charles River Laboratories International last closing stock price
MetricPriceDate
Last closeUSD 234.122026-08-04
Charles River Laboratories International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.62%USD 240.432026-07-28
1 month+1.49%USD 230.692026-07-02
3 month+28.83%USD 181.732026-05-06
Year to date+17.37%USD 199.482025-12-31
1 year+39.42%USD 167.922025-08-04
3 year+13.16%USD 206.902023-08-04
5 year-42.89%USD 409.972021-08-05
Since inception+964.18%USD 22.002000-06-23

Charles River Laboratories International Financials at a Glance

Market Cap

$11.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$4.03B

Net Income (TTM)

-$184.65M

EPS (TTM)

-$3.76

P/E Ratio

-62.26

Dividend

$0.00

Beta (Volatility)

1.28 (Average)

Price

$259.39

Volume

1,294,000.55

Open

$267.99

Previous Close

$234.12

Daily Range

$252.07 - $267.99

52-Week Range

$144.26 - $267.99

Estimated Earnings Date

Aug 5, 2026

CRL: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Charles River Laboratories International

Charles River helps drug companies test new medicines for safety and effectiveness. It provides specialized lab animals and technical support for scientific research. These services help doctors and scientists get life-saving treatments to patients faster.

The Science Behind the Solutions

  • Discovery and Safety Assessment: Laboratory services to identify drug candidates and test them for toxicity; represented 59.8% of total revenue in 2025.
  • Research Models and Services: Production of specialized rodents and large models for medical research; accounted for 21.1% of total revenue in 2025.
  • Manufacturing Solutions: Quality control testing for sterile products and specialized cell therapy production; generated 19.1% of total revenue in 2025.

New Moves and Acquisitions

  • Acquired Noveprim in 2023 to strengthen its supply chain for large research models.
  • Added Explora BioLabs in 2022 to expand its contract vivarium or leased lab space offerings.
  • Purchased assets of K.F. (Cambodia) Ltd. in January 2026 to secure its non-human primate supply.
  • Initiated a plan in late 2025 to sell non-core assets representing 7% of company revenue.

What Makes Charles River Different

The company operates a network of over 120 sites across more than 20 countries to support global drug developers. Its large-scale infrastructure allows it to serve as a single-source partner for both early-stage research and final product release testing.

Measuring the Money

  • Revenue reached $994.2 million in Q4 2025, a decrease of 0.8% year-over-year.
  • Gross profit grew to $307.9 million in Q4 2025, up 8.3% from the previous year.
  • Operating income rose to $120.2 million in Q4 2025, up 171.7% from a loss in Q4 2024.
  • Free cash flow was $58.6 million in Q4 2025, down 30.1% from Q4 2024.
  • Net income was a loss of $276.6 million in Q4 2025, down 28.2% from the prior year.

Bottom Line

Charles River has transitioned from a provider of research animals to an integrated partner for the global biotechnology industry. The company is currently focusing on optimizing its global footprint and streamlining its business to drive higher efficiency.

AI Generated • Apr 21, 2026

Industry

Life Sciences Tools and Services

Employees

19,700

CEO

James C. Foster

Headquarters

Wilmington, MA 01887, US

CRL Financials

Key Financial Metrics (TTM)

Gross Margin

31.86%

Operating Margin

11.77%

Net Income Margin

-4.59%

Return on Equity

-5.74%

Return on Capital

8.15%

Return on Assets

-2.39%

Earnings Yield

-1.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$11.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.17M

Volume

1.29M

Avg. Volume

901.17K

Financials (TTM)

Gross Profit

$1.28B

Operating Income

$474.05M

EBITDA

$290.56M

Operating Cash Flow

$607.03M

Capital Expenditure

-$215.74M

Free Cash Flow

$391.29M

Cash & ST Invst.

$191.83M

Total Debt

$3.06B

Charles River Laboratories International Performance Analysis

Charles River Laboratories International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,976,060,00012.3%
20232023-12-31USD 4,129,409,0003.9%
20242024-12-31USD 4,049,989,000-1.9%
20252025-12-31USD 4,015,382,000-0.9%
Charles River Laboratories International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-284.9%
Q32025-09-27-2.6%
Q42025-12-27-1.1%
Q12026-03-280.2%
Charles River Laboratories International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 9.4824.7%
20232023-12-31USD 9.22-2.7%
20242024-12-31USD 0.20-97.8%
20252025-12-31USD -2.91N/A
Charles River Laboratories International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-28112.0%
Q32025-09-273.8%
Q42025-12-27-610.9%
Q12026-03-2894.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$995.83M

+1.2%

Gross Profit

$279.32M

-12.1%

Gross Margin

28.05%

N/A

Market Cap

$11.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$572.44K

N/A

Employees

19,700

N/A

Net Income

-$14.84M

-158.3%

EBITDA

$63.95M

-65.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$191.83M

-16.4%

Total Debt

$3.06B

+2.4%

Accounts Receivable

$700.25M

-7.5%

Inventory

$359.72M

+24.0%

Long Term Debt

$3.06B

+2.4%

Short Term Debt

$0.00

N/A

Return on Assets

-2.39%

N/A

Return on Invested Capital

7.14%

N/A

Free Cash Flow

-$14.83M

-113.2%

Operating Cash Flow

$41.08M

-76.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DVADaVita Inc.
$188.81-17.18%
PENPenumbra, Inc.
$322.49-0.53%
RVTYRevvity, Inc.
$114.02+2.36%
BIOBio-Rad Laboratories, Inc.
$347.34+4.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$110.18-0.12%
NVDANvidia
$221.92+0.05%
ONDSOndas
$8.84-0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81-0.03%

Questions About CRL

What is the current price of Charles River Laboratories International?

Charles River Laboratories International is trading at $258.55 per share.

What is the 52-week range for Charles River Laboratories International?

Over the past 52 weeks, Charles River Laboratories International has traded between $144.26 and $267.99.

How much debt does Charles River Laboratories International have?

As of the most recent reporting period, Charles River Laboratories International reported total debt of $3.06B.

How much cash does Charles River Laboratories International have on hand?

Charles River Laboratories International reported $193.76M in cash and cash equivalents in its most recent financial results.

What is Charles River Laboratories International’s dividend yield?

Charles River Laboratories International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.